These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202). Nishida T; Shirao K; Sawaki A; Koseki M; Okamura T; Ohtsu A; Sugiyama T; Miyakawa K; Hirota S Int J Clin Oncol; 2008 Jun; 13(3):244-51. PubMed ID: 18553235 [TBL] [Abstract][Full Text] [Related]
27. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST). Hochhaus A Ann Hematol; 2004; 83 Suppl 1():S65-6. PubMed ID: 15124676 [No Abstract] [Full Text] [Related]
28. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Kantarjian HM; Cortes J; O'Brien S; Giles FJ; Albitar M; Rios MB; Shan J; Faderl S; Garcia-Manero G; Thomas DA; Resta D; Talpaz M Blood; 2002 May; 99(10):3547-53. PubMed ID: 11986206 [TBL] [Abstract][Full Text] [Related]
29. The development and application of imatinib. Jones RL; Judson IR Expert Opin Drug Saf; 2005 Mar; 4(2):183-91. PubMed ID: 15794712 [TBL] [Abstract][Full Text] [Related]
30. Initial treatment for patients with CML. Goldman JM Hematology Am Soc Hematol Educ Program; 2009; ():453-60. PubMed ID: 20008231 [TBL] [Abstract][Full Text] [Related]
31. [Tyrosine kinase inhibitors in the therapy of chronic myeloid leukaemia]. Grzybowska-Izydorczyk O; Góra-Tybor J; Robak T Postepy Hig Med Dosw (Online); 2006; 60():490-7. PubMed ID: 17013368 [TBL] [Abstract][Full Text] [Related]
33. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Kantarjian HM; Talpaz M; Giles F; O'Brien S; Cortes J Ann Intern Med; 2006 Dec; 145(12):913-23. PubMed ID: 17179059 [TBL] [Abstract][Full Text] [Related]
34. Imatinib mesylate. Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724 [No Abstract] [Full Text] [Related]
35. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Cortes JE; Talpaz M; Giles F; O'Brien S; Rios MB; Shan J; Garcia-Manero G; Faderl S; Thomas DA; Wierda W; Ferrajoli A; Jeha S; Kantarjian HM Blood; 2003 May; 101(10):3794-800. PubMed ID: 12560227 [TBL] [Abstract][Full Text] [Related]
36. Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. Wu J; Meng F; Kong LY; Peng Z; Ying Y; Bornmann WG; Darnay BG; Lamothe B; Sun H; Talpaz M; Donato NJ J Natl Cancer Inst; 2008 Jul; 100(13):926-39. PubMed ID: 18577747 [TBL] [Abstract][Full Text] [Related]
37. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571). Demetri GD Eur J Cancer; 2002 Sep; 38 Suppl 5():S52-9. PubMed ID: 12528773 [TBL] [Abstract][Full Text] [Related]
38. Successful pregnancy in a patient with chronic myeloid leukemia under treatment with imatinib. Tsuzuki M; Inaguma Y; Handa K; Hasegawa A; Yamamoto Y; Watanabe M; Mizuta S; Maruyama F; Okamoto M; Emi N Intern Med; 2009; 48(16):1433-5. PubMed ID: 19687593 [TBL] [Abstract][Full Text] [Related]
39. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Wolff NC; Veach DR; Tong WP; Bornmann WG; Clarkson B; Ilaria RL Blood; 2005 May; 105(10):3995-4003. PubMed ID: 15657179 [TBL] [Abstract][Full Text] [Related]
40. Elevations of creatine kinase in patients treated with imatinib mesylate (Gleevec). Gordon JK; Magid SK; Maki RG; Fleisher M; Berman E Leuk Res; 2010 Jun; 34(6):827-9. PubMed ID: 19963273 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]